INTRODUCTION Visceral leishmaniasis is an endemic protozoan found in Brazil. It is characterized by fever, pallor, hepatosplenomegaly, lymphadenopathy, and progressive weakness in the patient. It may lead to death if untreated. The drug of choice for treatment is meglumine antimoniate (Glucantime). The aim of this study was to evaluate patients with visceral leishmaniasis according to criteria ...

BACKGROUND Leishmaniasis is a parasitic disease caused by different species of Leishmania parasites with a wide range of clinical manifestations. Antimonial compounds such as meglumine antimoniate (glucantime) are the first line drugs for the treatment of leishmaniasis. However, according to reports of the drug resistance of parasites, the efficacy of antimonial compounds is low. The ATP-bindin...

Background and objective: Leishmaniasis is caused by protozoa of Leishmania genus and can be considered as a Zoonosis. The desease has caused the world health problems with high endemicity in developing countries such as Iran. Various chemical drugs have been used for leishmaniasis treatment, but their side effects and drug resistance haveled to look for new effective compounds. Medicago lupuli...

BACKGROUND Treatment of Cutaneous Leishmaniasis (CL) is being faced with serious difficulties in Fars Province, due to emerging of resistance against meglumine antimonite (Glucantime®). In this context, determining some biomarkers for drug sensitivity monitoring seems to be highly essential. Different studies have been carried out to decipher the genes might be involved in antimony resistant ph...

background: in this study, two-dimensional gel electrophoresis (2-de) method was applied to determine and compare the protein spots expressed in the two field isolates of leishmania major and recovered from the patients who were clinically sensitive and resistant to glucantime® treatment. methods: leishmania parasites were isolated from the cutaneous lesions of two cl infected patients in shira...

BACKGROUND Cutaneous leishmaniasis causes a high disease burden in Colombia, and available treatments present systemic toxicity, low patient compliance, contraindications, and high costs. The purpose of this study was to estimate the cost-effectiveness of thermotherapy versus Glucantime in patients with cutaneous leishmaniasis in Colombia. METHODS Cost-effectiveness study from an institutiona...

BACKGROUND American cutaneous leishmaniasis (ACL) is a complicated disease producing about 67.000 new cases per year. The severity of the disease depends on the parasite species; however in the vast majority of cases species confirmation is not feasible. WHO suggestion for ACL produced by Leishmania braziliensis, as first line treatment, are pentavalent antimonial derivatives (Glucantime or Sod...

BACKGROUND & OBJECTIVES Pentavalent antimony compounds are the first line of drugs in the treatment of cutaneous leishmaniasis. However, because of their potential toxic effects, many investigations are performed to find an effective and safe treatment for cutaneous leishmaniasis patients. Our objective in this investigation was to compare the effect of oral omeprazole and low dose systemic meg...